Abstract:While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously (IV)is recommended for pulmonary arterial hypertension (PAH) patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with PAH, why pPCY was refused and, in some cases, later accepted. Interviews were conducted with 25 PAH patients who previously refused pPCY therapy (Group A: Refused/Never Initiated [n=9] and Group B: Refused/Init… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.